Levin Capital Strategies L.P. Purchases 44,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Levin Capital Strategies L.P. increased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 440.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 54,000 shares of the company’s stock after acquiring an additional 44,000 shares during the period. Levin Capital Strategies L.P. owned approximately 0.08% of EyePoint Pharmaceuticals worth $402,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC increased its holdings in EyePoint Pharmaceuticals by 16.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company’s stock worth $9,583,000 after acquiring an additional 166,699 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in EyePoint Pharmaceuticals by 5.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock worth $1,141,000 after acquiring an additional 7,967 shares during the period. Barclays PLC increased its holdings in EyePoint Pharmaceuticals by 410.4% during the 3rd quarter. Barclays PLC now owns 245,045 shares of the company’s stock worth $1,959,000 after acquiring an additional 197,033 shares during the period. JPMorgan Chase & Co. increased its holdings in EyePoint Pharmaceuticals by 1,171.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company’s stock worth $2,970,000 after acquiring an additional 342,516 shares during the period. Finally, Franklin Resources Inc. increased its holdings in EyePoint Pharmaceuticals by 9.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company’s stock worth $32,056,000 after acquiring an additional 362,399 shares during the period. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Stock Performance

EYPT stock opened at $6.27 on Friday. EyePoint Pharmaceuticals, Inc. has a 52 week low of $5.78 and a 52 week high of $28.79. The firm’s fifty day moving average is $7.34 and its 200 day moving average is $8.51. The firm has a market cap of $427.93 million, a P/E ratio of -3.14 and a beta of 1.51.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on EYPT shares. Chardan Capital reissued a “buy” rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, February 6th. Citigroup started coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. Finally, Robert W. Baird decreased their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.